Next Article in Journal
Exploring Prescription Practices: Insights from an Antimicrobial Stewardship Program at a Tertiary Healthcare Facility, Rwanda
Previous Article in Journal
Accordance of Registered Drug Packages with Guideline-Recommended Treatment Durations for Community-Acquired Pneumonia—A New Antibiotic Stewardship Target?
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 13
Issue 6
10.3390/antibiotics13060547
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Urinary Tract Infections among Febrile Infants in Qatar: Extended-Spectrum-Beta-Lactamase (ESBL)-Producing Versus Non-ESBL Organisms

by
Mohammad Qusad
1,
Ihsan Elhalabi
1,
Samer Ali
1,
Khaled Siddiq
1,
Lujain Loay
1,
Abdallah Aloteiby
1,
Ghada Al Ansari
2,
Bassem Moustafa
1,
Tawa Olukade
3,
Mohammed Al Amri
3,
Ashraf Soliman
3 and
Ahmed Khalil
4,*
1
Section of Academic General Pediatrics, Department of Pediatrics, Hamad General Hospital, Doha 3050, Qatar
2
Department of Clinical Chemistry Laboratory, Hamad General Hospital, Doha 3050, Qatar
3
Department of Pediatrics, Hamad General Hospital, Doha 3050, Qatar
4
Section of Pediatric Clinical Pharmacy, Pharmacy Department, Hamad General Hospital, Doha 3050, Qatar
*
Author to whom correspondence should be addressed.
Antibiotics 2024, 13(6), 547; https://doi.org/10.3390/antibiotics13060547
Submission received: 8 May 2024 / Revised: 4 June 2024 / Accepted: 8 June 2024 / Published: 12 June 2024
Review Reports Versions Notes

Abstract

:
Background: The escalating prevalence of ESBL-producing Enterobacteriaceae in Qatar’s pediatric population, especially in community-onset febrile urinary tract infections (FUTIs), necessitates a comprehensive investigation into this concerning trend. Results: Over the course of one year, a total of 459 infants were diagnosed and subsequently treated for UTIs. Cases primarily occurred in infants aged over 60 days, predominantly non-Qatari females born from term pregnancies. Notably, E. coli and K. pneumoniae were the most frequently identified organisms, accounting for 79.7% and 9.8% in the ESBL group and 57.2% and 18.7% in the non-ESBL group, respectively. Interestingly, hydronephrosis emerged as the most prevalent urological anomaly detected in both ESBL (n = 10) and other organism (n = 19) groups. Methods: In this retrospective cohort study conducted in Qatar, we meticulously evaluated the prevalence of pediatric FUTIs. Our study focused on febrile infants aged less than 1 year, excluding those with urine samples not obtained through a catheter. Conclusions: E. coli and K. pneumoniae prevailed as the predominant causative agents in febrile children in Qatar, with hydronephrosis being identified as the most common urological anomaly. Moreover, our findings suggested that gentamicin served as a viable non-carbapenem option for hospitalized ESBL cases, while oral nitrofurantoin showed considerable promise for uncomplicated ESBL UTIs.

1. Introduction

Urinary tract infections (UTIs) are prevalent among children [1,2]. Up to 11% of children have experienced a UTI by the age of 16, with girls having a greater infection incidence than boys [3]. In pediatric clinical practice, the most prevalent confirmed bacterial infections are febrile urinary tract infections (FUTIs). FUTIs can cause significant morbidity and long-term consequences, such as renal scarring, hypertension and chronic renal failure [4,5]. Early detection and proper treatment decrease the probability of renal scarring and its related complications [6].
Extended-spectrum beta-lactamases (ESBLs) are a class of plasmid-encoding enzymes generated mostly by enterobacteria. The advent of extended-spectrum-β-lactamase-producing Enterobacteriaceae (ESBL-E) as a cause of FUTIs poses a severe concern to public health, with limited treatment options [7,8]. A few years ago, ESBL-E was primarily isolated in hospitals and other healthcare institutions.
The prevalence of ESBLs in urine among Qatar’s pediatric population has gradually increased (HMC yearly antibiogram) [9]. However, such organisms have disseminated throughout the population, and the prevalence of community-onset FUTIs caused by ESBL-E isolates has grown globally [10,11]. Not only ESBLs, but also uropathogenic Escherichia coli (E. coli) is responsible for 80–90% of pediatric UTIs [12], and the majority of FUTIs [13,14].
In Gulf Cooperation Council (GCC) countries (including Qatar), isolates producing ESBLs show resistance not only to cephalosporins and monobactams, but also to other antibiotic classes like aminoglycosides and fluoroquinolones [15]. Also, E. coli urine isolates from children in the GCC area (including Qatar) are highly resistant to popular antibiotics used to treat UTIs, such as ampicillin and trimethoprim/sulfamethoxazole [15].
The prevalence of urinary tract infections (UTIs) among febrile children in Qatar has not been comprehensively addressed in the existing literature. Thus, this study aims to provide a comprehensive assessment of the current prevalence of pediatric febrile UTIs (with a particular focus on extended-spectrum-beta-lactamase-producing organisms) in Qatar. It seeks to compare clinical histories, laboratory parameters and ultrasound findings related to urological abnormalities, as well as the types of antibiotics used and their routes of administration between ESBL and non-ESBL organisms.

2. Results

For one year, 459 infants were diagnosed and treated for UTIs. The study identified a prevalence of 16.1 ESBL-producing UTI cases per 1000 pediatric admissions among infants with suspected urinary tract infections. Most of these infants (n = 403, 87.8%) were aged over 60 days at the time of presentation, non-Qatari (n = 379, 82.6%) and female (n = 298, 65%). Most infants (87.5%) were born from term pregnancies and 31.7% of male infants were circumcised, as detailed in (Table 1).
The most frequently isolated uropathogens were Escherichia coli and Klebsiella pneumoniae. Escherichia coli predominated as the primary ESBL uropathogen (79.7%). No significant differences were observed in the demographic variables between the ESBL and non-ESBL organism groups (Table 2).
Table 3 presents the findings about significant clinical histories, laboratory parameters and imaging abnormalities detected in US or VCUG among patients infected with ESBL-producing organisms compared to those infected with non-ESBL pathogens. Several of these findings were clinically relevant. Notably, the ESBL group demonstrated a higher prevalence of urine WBCs compared to non-ESBL organisms (80.8% vs. 64.9%, respectively; p < 0.001), as per clinical guidelines. This pattern was also observed for the urine analysis of leukocytes (54.2% vs. 42.5%, p = 0.023) and nitrites (38.9% vs. 24.2%, p = 0.002), respectively. While there was a noticeable difference in creatinine levels between the two groups, it did not have much clinical impact, as it remained within normal ranges for their respective age groups. Moreover, although not statistically significant, it is worth mentioning that the ESBL group tended to have higher median values for inflammatory markers compared to the group infected with non-ESBL organisms. These markers included the white blood cell count (13.3 vs. 12), absolute neutrophil count (5.8 vs. 4.9), C-reactive protein (29 vs. 17.4) and platelet count (407 vs. 373). Additionally, there were no significant differences observed in other measured factors, such as admission to the neonatal intensive care unit (NICU), previous hospitalizations or surgeries, known urinary system abnormalities, abnormalities detected using VCUG or US, circumcision status among male infants or previous positive urine cultures.
The US evaluation of the kidneys and urinary tract revealed abnormalities in only 35 cases (11 within the ESBL group and 24 among those infected with non-ESBL organisms). Hydronephrosis emerged as the most common pathology, followed by dysplastic kidney, horseshoe kidney, ectopic kidney and duplex collecting system, as outlined in (Table 4).
Table 5 outlines the utilization of antibiotics (expressed in percentages) among infants diagnosed with ESBL infections compared to those with infections from non-ESBL organisms, including their administration routes. Overall, a higher proportion of infants in the ESBL group (56.5%) received intravenous (IV) antibiotics compared to those infected with non-ESBL organisms (34.4%). In the high-risk, complicated ESBL UTI group, gentamicin (36.4%) emerged as the primary antibiotic choice, followed by nitrofurantoin (11.4%) for noncomplicated cases managed as outpatients in the emergency department. Empirical treatment with ceftriaxone (9.1%) and cefixime (22.7%) was initiated depending on the severity of the case and hospitalization status, with subsequent adjustments based on sensitivity results to gentamicin and nitrofurantoin, respectively. In contrast, for the non-ESBL organism group, cefixime (45.1%) was the predominant oral antibiotic prescribed for outpatient cases, then amoxicillin/clavulanate (15.4%), while ceftriaxone (21.9%) was the most used IV antibiotic for hospitalized inpatient cases.

3. Discussion

Through this retrospective cohort study, we highlighted the prevalence of pediatric FUTIs and compared clinical histories, laboratory parameters, US urological abnormalities and the antibiotics used and their routes of administration between ESBL and non-ESBL organisms among infants who were admitted to the Hamad General Hospital (pediatric emergency center and inpatient unit). The study identified a prevalence of 16.1 ESBL-producing UTI cases per 1000 pediatric admissions among infants with suspected urinary tract infections (UTIs). Hanna-Wakim et al. evaluated hospitalized children over ten years and reported a positivity ESBL rate of 15.5%, which closely aligned with our findings [13]. Additionally, a recent systematic review and meta-analysis revealed a pooled prevalence of pediatric ESBL UTIs of 5% in Eastern Mediterranean studies, contrasting with an overall prevalence of 14% in all other countries [16]. This indicated regional variations in ESBL prevalence. Notably, some regions reported significantly higher rates; for instance, a cohort study from Turkey and Jordan documented prevalence rates as high as 46% and 49.3%, respectively [17,18]. These higher rates could be attributed to differences in antibiotic usage patterns, healthcare practices and the effectiveness of infection control measures. Our study’s prevalence fell within the range reported by other studies, highlighting the ongoing global challenge of managing ESBL-producing bacterial infections in pediatric populations. These findings underscored the importance of continuous surveillance, effective antibiotic stewardship and robust infection control measures to mitigate the impact of these resistant pathogens.
With regard to the demographic characteristics, most of the infants were female in both the ESBL group (65.4%) and non-ESBL organism group (64.7%). Similarly, Awean GZA et al.’s study in Qatar showed that most of the infected patients were female in ESBL bacteria (78%) and non-ESBL bacteria (76.8%) [19], while Han et al.’s study showed that most of the infected patients were male in the ESBL group (52.4%) and non-ESBL group (60%) [20].
The nationality distribution, which was similar to the overall distribution, showed that most of infants were non-Qatari in the ESBL group (85.7%) and in the non-ESBL organism group (81.3%). Likewise, Awean GZA et al.’s study showed that most of the infected patients were non-Qatari in the ESBL group (85.3%) and non-ESBL group (75.3%) [19].
In terms of the infants’ age distribution, the majority of infants in both the ESBL group (91%) and the non-ESBL organism group (86.5%) were over 2 months old, aligning with established trends. Notably, the study by Park SY and Kim JH revealed that the mean age of infants in the ESBL group (4.31 months old) was younger than those in the non-ESBL group (6.26 months old). Conversely, Kim YH et al. found that the mean age of infants in the ESBL group (4.2 months old) was older than in the non-ESBL group (3.1 months old) [21,22]. Furthermore, Awean GZA et al. observed that the majority of infected infants were under 1 year old in both the ESBL group (45.6%) and the non-ESBL group (39.2%) [19]. Additionally, a trend regarding a higher incidence of ESBL cases in children less than a year old was noted, which was consistent with findings from two studies conducted in Turkey and Jordan [17,18].
In examining the prevalence of urinary organisms, E. coli and Klebsiella pneumoniae (K. pneumoniae) emerged as the predominant strains encountered within the ESBL group, accounting for 79.7% and 9.8% of cases, respectively. Meanwhile, within the group of other organisms, E. coli and K. pneumoniae were also prevalent, though to a lesser extent, constituting 57.2% and 18.7% of cases, respectively. When exploring existing research, findings from the study conducted by Park SY and Kim JH underscored E. coli’s predominance as the most frequently encountered organism in both ESBL and non-ESBL groups, accounting for 100% and 89% of cases, respectively. Following E. coli, K. pneumoniae and Enterobacter spp. were noted in the non-ESBL group, comprising 4% and 3% of cases, respectively. Similarly, Han et al. corroborated these trends, indicating E. coli and K. pneumoniae as the leading organisms in both ESBL and non-ESBL groups, with proportions of 42.9% and 50% in the former and 50% each in the latter. Aligning with these observations, the study conducted by Awean GZA et al. in Qatar revealed a similar pattern, with E. coli and Klebsiella species predominating in both ESBL and non-ESBL groups, albeit with varying proportions. Specifically, E. coli and Klebsiella species were identified in 32.4% and 32% of cases in the ESBL group and in 67.6% and 68% of cases in the non-ESBL group, respectively [19,20,21].
Regarding laboratory parameters, the WBC median was higher within the ESBL group (13.3 × 103/mm3) compared to the non-ESBL organism group (12 × 103/mm3). Notably, the analysis revealed that the differences in the WBC counts between the groups were not significant, with values being similar. This was consistent with findings from Park SY and Kim JH’s study, which showed comparable WBC means between the ESBL group (13.4 × 103/μL) and the non-ESBL group (13.7 × 103/μL). Similarly, Kim YH et al.’s study reported similar WBC means in the ESBL group (14.4 × 103/mm3) and the non-ESBL group (15.5 × 103/mm3), and N.C. Fan et al.’s study also found comparable WBC means between the ESBL group (12,517.1/μL) and the non-ESBL group (13,304.4/μL) [21,22,23].
The median platelet count among infants in the ESBL group was (407 × 103/μL) compared to (373 × 103/μL) in the non-ESBL organism group. However, this disparity in platelet counts between the groups did not reach statistical significance. These observations aligned with the conclusions drawn in Park SY and Kim JH’s study, which highlighted the comparability of platelet means between the ESBL group (442 × 103/μL) and the non-ESBL group (428 × 103/μL). Similarly, N.C. Fan et al.’s study also corroborated these findings, reporting analogous platelet means between the ESBL group (348 × 103/μL) and the non-ESBL group (342 × 103/μL) [21,23].
For creatinine, we observed a similarity in levels between the two groups. Among infants in the ESBL group, the median creatinine level (20 umol/L) closely approximated that of the other organism group (22 umol/L). These findings were in line with the results reported by Park SY and Kim JH, where the mean creatinine levels exhibited comparability between the ESBL group (20.3 umol/L) and the non-ESBL group (19.4 umol/L). However, it is noteworthy to mention that N.C. Fan et al.’s study recorded higher creatinine levels in both groups, with the ESBL group (35 umol/L) and the non-ESBL group (53 umol/L) demonstrating elevated values compared to those observed in our study [21,23].
We observed a higher median level of C-reactive protein (CRP) among infants in the ESBL group (29 mg/L) compared to the group infected with non-ESBL organisms (17.4 mg/L). These results mirrored the findings of previous research conducted in Park SY and Kim JH’s study, which similarly reported elevated CRP levels in the ESBL group (45.5 mg/L) compared to non-ESBL group (43.5 mg/L). However, it is noteworthy that the observed differences did not reach statistical significance in either our study or theirs [21].
The number of previous hospitalizations significantly differed among infants in the ESBL group (n = 12) compared to those infected with non-ESBL organisms (n = 26), although this difference was not statistically significant. This observation was consistent with findings from Park SY and Kim JH’s study, which similarly reported a lower number of previous hospitalizations in the ESBL group (n = 10) compared to the non-ESBL group (n = 39). It is important to note, however, that in their investigation, this variation reached statistical significance with a p-value of 0.02 [21].
The presence of urological anomalies identified via voiding cystourethrogram (VCUG) was less frequent among infants in the ESBL group (n = 3) compared to those infected with non-ESBL organisms (n = 6). Similarly, Awean GZA et al.’s study demonstrated a lower occurrence of urological anomalies via VCUG in the ESBL group (n = 6) compared to the group infected with non-ESBL organisms (n = 8) [19]. Moreover, the presence of urological anomalies identified via ultrasonography (US) was less frequent among infants in the ESBL group (n = 11) compared to those in the non-ESBL organism group (n = 24). Awean GZA et al.’s study also supported this observation, showing a lower presence of urological anomalies via US in the ESBL group (n = 11) compared to the group infected with non-ESBL organisms (n = 18) [19]. When examining specific urological anomalies identified via US, hydronephrosis emerged as the most prevalent anomaly among infants in both the ESBL group (n = 10) and the non-ESBL organism group (n = 19). This finding aligned with the results of Park SY and Kim JH’s study, where hydronephrosis was similarly prevalent among both the ESBL group (n = 7) and the non-ESBL organism group (n = 36) [21].
Based on our analysis of antibiotic usage, we found that both oral and intravenous routes were commonly employed in treating infants. In the ESBL group, antibiotics were predominantly administered intravenously (56.9%), whereas in the non-ESBL organism group, they were administered via both oral (65.6%) and intravenous (34.4%) routes. Inpatient treatment protocols for infants aged younger than 2 months typically comprised intravenous third-generation cephalosporins, notably ceftriaxone and cefotaxime, targeting non-ESBL organisms, consistent with the findings reported by Zorc et al. and in other studies [14,24,25]. Aminoglycosides, including gentamycin and amikacin, demonstrated complete sensitivity throughout the study period. Notably, gentamycin emerged as the most frequently administered non-carbapenem antimicrobial agent for ESBL cases, followed by amikacin, corroborating earlier studies by Jo et al. and Joo and Shin [26,27]. In older infants aged over 2 months, oral cefixime and amoxicillin/clavulanate emerged as the most prescribed antibiotic for non-resistant organisms, in line with our observation. For noncomplicated ESBL cases, oral treatments like nitrofurantoin and sulfamethoxazole/trimethoprim were utilized, mirroring the findings of studies conducted by Raman G. et al., Robinson JL et al. and Wang ME et al. [28,29,30].
While this study provided valuable insights, it is essential to acknowledge its limitations. The data reviewed were confined to a single medical center and spanned only one year, potentially limiting their generalizability to the broader national landscape of microbial etiology and antibiotic resistance in ESBL UTIs. Nonetheless, this study holds significance, as it represents a pioneering effort in characterizing long-term surveillance data for UTIs among all pediatric patients in a tertiary referral hospital in Qatar. Notably, our center stands as the largest pediatric facility in Qatar, further underscoring the importance of this study in addressing a critical gap in understanding and managing UTIs in this population.

4. Methods

4.1. Study Design, Setting and Participants

This retrospective cohort study was based on routinely collected hospital data of febrile infants over a 12-month period from January to December 2019. The population consisted of infants aged less than one year. The investigation was primarily conducted at Hamad General Hospital (inpatient pediatric unit) and the El-Sad center, the largest emergency center in the state of Qatar, a cosmopolitan hub where a diversity of patients from different countries reside. In 2019, a total of 8237 pediatric patients were admitted to the hospital. The study included 459 of these pediatric patients.
The identification and susceptibility profiling of all bacteria from positive urine cultures were determined by using an automated susceptibility system VITEK 2 (Bio Merieux, Marcy l Etoile, France), according to the Clinical and Laboratory Standard Institute guidelines (CLSI).
The inpatient treatment at the UTI ward for infants aged 0–1 month with a febrile UTI or pyelonephritis recommended a treatment duration of 10–14 days. For infants older than 1 month with bacteremia due to urosepsis, there is no evidence suggesting that a prolonged course of parenteral antibiotics reduces the chance of a relapse. These infants can transition to oral antibiotics once they become afebrile and a repeat blood culture remains negative for 48 h. For uncomplicated UTIs in this age group, the treatment course is typically 5–7 days. However, for complicated UTIs, pyelonephritis, or in cases where the child is 2 months or younger, a 10–14-day treatment course is necessary. Complicated UTIs include conditions such as UTIs in the presence of renal calculi, in immunocompromised hosts or those presenting with severe illness like septic shock [31,32].

4.2. Inclusion and Exclusion Criteria

The study included patients who met the following inclusion criteria: febrile infants exhibiting symptoms suggestive of a urinary tract infection (UTI) and undergoing urine sample collection for microscopy and culture before commencing antibiotic treatment; positive findings of pyuria and bacteriuria on urine microscopy coupled with leukocyte esterase and nitrites positive on a urine dipstick analysis; additionally, culture results meeting the defined thresholds for a UTI, such as >50,000 colony-forming units per milliliter (cfu/mL) in catheterized samples or any growth in suprapubic aspiration [31,32].
The exclusion criteria included infants previously treated with antibiotics before urine sample collection, potentially leading to false negative results. Additionally, cases lacking pyuria and bacteriuria in urine microscopy and samples collected via a bag instead of a catheter were excluded due to potential contamination and unreliable results.

4.3. Data Collection and Study Variables

We retrieved data relating to patients’ demographics, past medical history, treatment given and laboratory and radiology data related to this study objective from electronic medical records. We extracted demographic variables of age and grouped participants as less than or equal to 60 days old or greater than 60 days of age at presentation, nationality as Qatari and non-Qatari and gender as male or female. We retrieved past medical histories of gestational age, neonatal intensive care unit (NICU) admission, circumcision status for males and history of previous UTIs or hospital admissions including the history of coexisting urogenital abnormalities. The laboratory parameters retrieved included the hemoglobin level, total white blood cell count (WBC), absolute neutrophil count (ANC), platelet count, C-reactive protein (CRP), sodium, blood urea nitrogen (BUN), creatinine (Cr) levels, urine WBC, nitrite and leukocytes.
Results for the urine extracted were grouped as ESBL-producing uropathogens or non-ESBL organisms. The non-ESBL group comprised both Gram-negative and other Gram-positive organisms detected in the urine culture for our pediatric cases. Finally, we extracted results for voiding cystourethrogram (VCUG) and US, the antibiotic used and the route utilized. Most variables were studied as dichotomized variables. The comparison groups were the ESBL versus non-ESBL organisms group from urine cultures.

4.4. Ethical Approval

The study was approved by the institutional review boards of the Hamad Medical Corporation (MRC-01-22-753). The requirement for consent was waived because of the retrospective nature of the study.

4.5. Statistical Analysis

We summarized the distribution of variables using numbers and percentages, and median and interquartile ranges as appropriate. To compare the ESBL with non-ESBL organisms, we used chi-square tests or the Mann–Whitney U test. A statistical analysis was performed using IBM SPSS 28 statistical software with a statistical significance set at p < 0.05.

5. Conclusions

Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) emerged as the predominant organisms encountered in extended-spectrum beta-lactamase (ESBL) and other bacterial groups among febrile children in Qatar. Notably, hydronephrosis emerged as the most prevalent urological anomaly detected through voiding cystourethrogram (VCUG) and ultrasonography (US) screenings among infants. Gentamicin, as a non-carbapenem alternative, emerged as a favorable option for treating pediatric ESBL urinary tract infections (UTIs), exhibiting promising efficacy. Additionally, nitrofurantoin demonstrated efficacy as an oral antibiotic for managing uncomplicated ESBL UTIs, offering a valuable therapeutic option in such cases.

Author Contributions

Conceptualization, M.Q. and M.A.A.; Methodology, L.L. and T.O.; Validation, A.A.; Formal Analysis, I.E., S.A., A.A., B.M., T.O., A.S. and A.K.; Investigation, K.S.; Resources, A.A., G.A.A. and M.A.A.; Data Curation, I.E., S.A., K.S., L.L., G.A.A. and B.M.; Writing—Original Draft, A.S. and A.K.; Writing—Review and Editing, M.Q. and A.K.; Visualization, M.A.A.; Supervision, A.K. All authors have read and agreed to the published version of the manuscript.

Funding

This article’s publication was funded by the Medical Research Center (MRC) of the Hamad Medical Corporation (HMC).

Institutional Review Board Statement

The study was conducted in accordance with the principles of the Declaration of Helsinki, Good Clinical Practice (GCP) and in compliance with the laws and regulations of the Ministry of Public Health (MOPH) in Qatar. The study received approval from the institutional review board (IRB) committee of the Medical Research Center (MRC), Doha, Qatar, with the number (MRC-01-22-753).

Informed Consent Statement

Patient consent was waived by the research committee for the study given its retrospective approach.

Data Availability Statement

Upon reasonable request, the primary author can provide the raw data supporting the conclusions of this article.

Acknowledgments

All authors devoted significant contributions to the work reported, whether in the conception, study design, execution, acquisition of data, analysis, interpretation or in all these areas. All authors took part in drafting, revising or critically reviewing the article, gave final approval of the version to be published, agreed on the journal to which the article has been submitted and agree to be accountable for all aspects of the work.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Foxman, B.; Brown, P. Epidemiology of urinary tract infections. Infect. Dis. Clin. N. Am. 2003, 17, 227–241. [Google Scholar] [CrossRef]
  2. Zhu, C.; Wang, D.-Q.; Zi, H.; Huang, Q.; Gu, J.-M.; Li, L.-Y.; Guo, X.-P.; Li, F.; Fang, C.; Li, X.-D.; et al. Epidemiological trends of urinary tract infections, urolithiasis and benign prostatic hyperplasia in 203 countries and territories from 1990 to 2019. Mil. Med. Res. 2021, 8, 64. [Google Scholar] [CrossRef]
  3. Shaikh, N.; Morone, N.E.; Bost, J.E.; Farrell, M.H. Prevalence of Urinary Tract Infection in Childhood. Pediatr. Infect. Dis. J. 2008, 27, 302–308. [Google Scholar] [CrossRef]
  4. Montini, G.; Tullus, K.; Hewitt, I. Febrile Urinary Tract Infections in Children. N. Engl. J. Med. 2011, 365, 239–250. [Google Scholar] [CrossRef]
  5. Jacobson, S.H.; Eklöf, O.; Eriksson, C.G.; Lins, L.E.; Tidgren, B.; Winberg, J. Development of hypertension and uraemia after pyelo-nephritis in childhood: 27 year follow up. BMJ 1989, 299, 703–706. [Google Scholar] [CrossRef]
  6. Shaikh, N.; Mattoo, T.K.; Keren, R.; Ivanova, A.; Cui, G.; Moxey-Mims, M.; Majd, M.; Ziessman, H.A.; Hoberman, A. Early Antibiotic Treatment for Pediatric Febrile Urinary Tract Infection and Renal Scarring. JAMA Pediatr. 2016, 170, 848–854. [Google Scholar] [CrossRef]
  7. Pitout, J.D.; Laupland, K.B. Extended-spectrum β-lactamase-producing Enterobacteriaceae: An emerging public-health concern. Lancet Infect. Dis. 2008, 8, 159–166. [Google Scholar] [CrossRef]
  8. Livni, G.; Ashkenazi, S. Treatment of resistant bacterial infections in children: Thinking inside and outside the box. Adv. Exp. Med. Biol. 2013, 764, 123–132. [Google Scholar] [CrossRef]
  9. Eltai, N.O.; Al Thani, A.A.; Al-Ansari, K.; Deshmukh, A.S.; Wehedy, E.; Al-Hadidi, S.H.; Yassine, H.M. Molecular characterization of extended spectrum β-lactamases enterobacteriaceae causing lower urinary tract infection among pediatric population. Antimicrob. Resist. Infect. Control 2018, 7, 90. [Google Scholar] [CrossRef]
  10. Rodríguez-Baño, J.; Alcalá, J.C.; Cisneros, J.M.; Grill, F.; Oliver, A.; Horcajada, J.P.; Tórtola, T.; Mirelis, B.; Navarro, G.; Cuenca, M.; et al. Community infections caused by extend-ed-spectrum beta-lactamase-producing Escherichia coli. Arch. Intern. Med. 2008, 168, 1897–1902. [Google Scholar] [CrossRef]
  11. Apisarnthanarak, A.; Kiratisin, P.; Mundy, L.M. Predictors of mortality from community-onset bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infect. Control Hosp. Epidemiol. 2008, 29, 671–674. [Google Scholar] [CrossRef]
  12. Leung, A.K.C.; Wong, A.H.C.; Leung, A.A.M.; Hon, K.L. Urinary Tract Infection in Children. Recent Pat. Inflamm. Allergy Drug Discov. 2019, 13, 2–18. [Google Scholar] [CrossRef]
  13. Hanna-Wakim, R.H.; Ghanem, S.T.; El Helou, M.W.; Khafaja, S.A.; Shaker, R.A.; Hassan, S.A.; Saad, R.K.; Hedari, C.P.; Khinkarly, R.W.; Hajar, F.M.; et al. Epidemiology and characteristics of urinary tract infections in children and adolescents. Front. Cell. Infect. Microbiol. 2015, 5, 45. [Google Scholar] [CrossRef]
  14. Zorc, J.J.; Kiddoo, D.A.; Shaw, K.N. Diagnosis and Management of Pediatric Urinary Tract Infections. Clin. Microbiol. Rev. 2005, 18, 417–422. [Google Scholar] [CrossRef]
  15. Bryce, A.; Hay, A.D.; Lane, I.F.; Thornton, H.V.; Wootton, M.; Costelloe, C. Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by Escherichia coli and association with routine use of antibiotics in primary care: Systematic review and meta-analysis. BMJ 2016, 352, i939. [Google Scholar] [CrossRef]
  16. Flokas, M.E.; Detsis, M.; Alevizakos, M.; Mylonakis, E. Prevalence of ESBL-producing Enterobacteriaceae in paediatric urinary tract infections: A systematic review and meta-analysis. J. Infect. 2016, 73, 547–557. [Google Scholar] [CrossRef]
  17. Topaloglu, R.; Er, I.; Dogan, B.G.; Bilginer, Y.; Ozaltin, F.; Besbas, N.; Ozen, S.; Bakkaloglu, A.; Gur, D. Risk factors in community-acquired urinary tract infections caused by ESBL-producing bacteria in children. Pediatr. Nephrol. 2010, 25, 919–925. [Google Scholar] [CrossRef]
  18. Albaramki, J.H.; Abdelghani, T.; Dalaeen, A.; Ahmad, F.K.; Alassaf, A.; Odeh, R.; Akl, K. Urinary tract infection caused by extended-spectrum β-lactamase-producing bacteria: Risk factors and antibiotic resistance. Pediatr. Int. 2019, 61, 1127–1132. [Google Scholar] [CrossRef]
  19. Awean, G.Z.; Salameh, K.; Elmohamed, H.; Alshmayt, H.; Omer, M.R.B. Prevalence of ESBL urinary tract infection in children. J. Adv. Pediatr. Child Health 2019, 2, 4–7. [Google Scholar] [CrossRef]
  20. Han, S.B.; Jung, S.W.; Bae, E.Y.; Lee, J.W.; Lee, D.-G.; Chung, N.-G.; Jeong, D.C.; Cho, B.; Kang, J.H.; Kim, H.-K.; et al. Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Bacteremia in Febrile Neutropenic Children. Microb. Drug Resist. 2015, 21, 244–251. [Google Scholar] [CrossRef]
  21. Park, S.Y.; Kim, J.H. Clinical Significance of Extended-spectrum β-lactamase-producing Bacteria in First Pediatric Febrile Urinary Tract Infections and Differences between Age Groups. Child. Kidney Dis. 2017, 21, 128–135. [Google Scholar] [CrossRef]
  22. Kim, Y.H.; Yang, E.M.; Kim, C.J. Urinary tract infection caused by community-acquired extended-spectrum β-lactamase-producing bacteria in infants. J. Pediatr. 2017, 93, 260–266. [Google Scholar] [CrossRef]
  23. Fan, N.-C.; Chen, H.-H.; Chen, C.-L.; Ou, L.-S.; Lin, T.-Y.; Tsai, M.-H.; Chiu, C.-H. Rise of community-onset urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli in children. J. Microbiol. Immunol. Infect. 2013, 47, 399–405. [Google Scholar] [CrossRef] [PubMed]
  24. Gauthier, M.; Chevalier, I.; Sterescu, A.; Bergeron, S.; Brunet, S.; Taddeo, D. Treatment of Urinary Tract Infections among Febrile Young Children with Daily Intravenous Antibiotic Therapy at a Day Treatment Center. Pediatrics 2004, 114, e469–e476. [Google Scholar] [CrossRef] [PubMed]
  25. Doré-Bergeron, M.-J.; Gauthier, M.; Chevalier, I.; McManus, B.; Tapiero, B.; Lebrun, S. Urinary Tract Infections in 1- to 3-Month-Old Infants: Ambulatory Treatment with Intravenous Antibiotics. Pediatrics 2009, 124, 16–22. [Google Scholar] [CrossRef] [PubMed]
  26. Jo, K.J.; Yoo, S.; Song, J.Y.; Kim, S.H.; Park, S.E. Non-carbapenem antimicrobial therapy in young infant with urinary tract infections caused by community-acquired extended-spectrum β-lactamase-producing Escherichia coli. Pediatr. Neonatol. 2021, 62, 271–277. [Google Scholar] [CrossRef] [PubMed]
  27. Jung, H.J.; Lee, S.Y. 1472. Non-Carbapenems for Treating Community-Associated Urinary Tract Infection Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Children. Open Forum Infect. Dis. 2019, 6, S537. [Google Scholar] [CrossRef]
  28. Raman, G.; McMullan, B.; Taylor, P.; Mallitt, K.-A.; E Kennedy, S. Multiresistant E. coli urine infections in children: A case–control study. Arch. Dis. Child. 2017, 103, 336–340. [Google Scholar] [CrossRef]
  29. Robinson, J.L.; Finlay, J.C.; Lang, M.E.; Bortolussi, R. Urinary tract infections in infants and children: Diagnosis and management. Paediatr. Child Health 2014, 19, 315–319. [Google Scholar] [CrossRef]
  30. Wang, M.E.; Lee, V.; Greenhow, T.L.; Beck, J.; Bendel-Stenzel, M.; Hames, N.; McDaniel, C.E.; King, E.E.; Sherry, W.; Parmar, D.; et al. Clinical Response to Discordant Therapy in Third-Generation Cephalosporin-Resistant UTIs. Pediatrics 2020, 145, e20191608. [Google Scholar] [CrossRef]
  31. Ministry of Public Health Qatar. National Clinical Guideline: The Diagnosis and Management of Urinary Tract Infections in Children. 2019. Available online: https://www.moph.gov.qa/_layouts/download.aspx?SourceUrl=/Admin/Lists/ClinicalGuidelinesAttachments/Attachments/67/The%20Diagnosis%20and%20Management%20of%20Urinary%20Tract%20Infections%20in%20Children.pdf (accessed on 20 January 2024).
  32. National Institute for Health and Clinical Excellence (NICE). Urinary Tract Infection in Under 16s: Diagnosis and Management. NICE Guideline NG54. Available online: https://www.nice.org.uk/guidance/ng54 (accessed on 24 January 2024).
Table 1. Population characteristics.
Table 1. Population characteristics.
VariablesTotalESBLNon-ESBL Urinary Organismsp-Value †
(n = 459)(n = 133)(n = 326)
n (%)n (%)n (%)
Gender 0.888
Male161 (35)46 (34.6)115 (35.3)
Female298 (65)87 (65.4)211 (64.7)
Ethnicity 0.257
Non-Qatari379 (82.6)114 (85.7)265 (81.3)
Qatari80 (17.4)19 (14.3)61 (18.7)
Age Group 0.184
>60 days403 (87.8) 121 (91)282 (86.5)
≤60 days56 (12.2)12 (9)44 (13.5)
Gestational Age 0.208
≥37 weeks321 (87.5)80 (82.5)241 (89.3)
32–36 weeks39 (10.6) 14 (14.4)25 (9.3)
≤31 weeks7 (1.9)3 (3.1)4 (1.5)
Male circumcision 0.857
Not circumcised69 (68.3)14 (70)55 (67.9)
Circumcised32 (31.7)6 (30)26 (32.1)
† Statistical significance was set at p < 0.05.
Table 2. Prevalence of urinary organisms.
Table 2. Prevalence of urinary organisms.
Urine OrganismESBLNon-ESBL Urinary Organisms
n = 133%n = 326%
Escherichia coli10679.718757.2
Klebsiella pneumoniae139.86118.7
Enterococcus faecalis--288.6
Proteus mirabilis00103.1
Citrobacter koseri0092.8
Pseudomonas aeruginosa0092.8
Streptococcus agalactiae--82.5
Klebsiella oxytoca0051.5
Enterobacter cloacae4310.3
Citrobacter freundii32.300
Staphylococcus aureus--30.9
Serratia marcescens10.820.6
Citrobacter amalonaticus10.800
Enterobacter gergoviae10.800
Enterococcus raffinosus0010.3
Klebsiella aerogenes10.800
Klebsiella ozaenae0010.3
Morganella morganii10.810.3
Proteus hauseri0010.3
Streptococcus gallolyticus--10.3
Table 3. Clinical history and laboratory parameters between ESBL and non-ESBL urinary organisms.
Table 3. Clinical history and laboratory parameters between ESBL and non-ESBL urinary organisms.
ESBL
(n = 133)		Non-ESBL
(n = 326)		p-Value †
Laboratory Parameters and Clinical HistoryMedianIQRMedianIQR
WBCs 13.38.3–18.3128.6–16.80.251
ANCs5.82.6–9.34.92.8–8.10.434
Platelets407303–476373301–4540.205
CRP (mg/L)296.3–5517.45–520.446
Na level138136–139137136–1380.314
BUN level2.71.9–3.732.1–3.90.124
Creatinine level2017–232219–26<0.001
n%n%p-value
Urine WBCs (>9)10580.8%20964.9%<0.001
UA leukocytes (≥trace)7154.2%13542.5%0.023
UA nitrites 5138.9%7724.2%0.002
NICU admission 3129.2%6121.9%0.129
Previous hospitalization 1210.2%268.4%0.576
Previous surgeries00%20.6%NA
Presence of renal/urogenital anomalies/diseases109.4%176.4%0.303
Presence of urological anomalies using VCUG35.7%65.1%0.572
Abnormal US result1112%2412.8%0.847
Circumcised630%2632.1%0.857
Previous positive urine culture 108.3%269.8%0.637
Note: † p < 0.05. Abbreviations: WBCs—white blood cells; ANCs—absolute neutrophil count; CRP—C-reactive protein; BUN—blood urea nitrogen; VCUG—voiding cystourethrogram; US—ultrasound.
Table 4. Ultrasound urological abnormality across ESBL and non-ESBL urinary organisms.
Table 4. Ultrasound urological abnormality across ESBL and non-ESBL urinary organisms.
Abnormality ESBLNon-ESBL Urinary Organisms
n (%)n (%)
Hydronephrosis 10 (10.9)19 (10.1)
Dysplastic kidney0 (0)1 (0.5)
Horseshoe kidney0 (0)1 (0.5)
Ectopic kidney0 (0)2 (1.1)
Duplex collecting system1 (1.1)1 (0.5)
Table 5. Antimicrobial use and administration routes for ESBL and non-ESBL urinary organisms.
Table 5. Antimicrobial use and administration routes for ESBL and non-ESBL urinary organisms.
OrganismnRoute (%)† (IV)                                                            Antibiotic (%)(Oral)
Oral
n (%)		† IV
n (%)		Ceftriaxone Gentamicin Amoxicillin AmpicillinTazocin *** Cefepime CefotaximeErtapenemAmikacin Meropenem Cefixime Amox/Clav * Cefuroxime Nitrofurantoin TMP–SMX ** Cefdinir
Non-ESBLEscherichia coli187132 (70.6)55 (29.4)213.80.5 0.5 2.2 51.1143.22.21.6
Klebsiella pneumoniae6140 (65.6)21 (34.4)203.3 1.75 1.7 41.7205 1.7
Enterococcus faecalis2817 (60.7)11 (39.3)23.1 7.77.7 30.819.2 11.5
Proteus mirabilis108 (80)2 (20)10 304020
Citrobacter koseri96 (66.6)3 (33.3)33.3 55.611.1
Pseudomonas aeruginosa91 (11.1)8 (88.9)11.166.7 11.1 11.1
Streptococcus agalactiae81 (12.5)7 (87)42.9 14.3 14.3 14.314.3
Klebsiella oxytoca52 (40)3 (60)60 40
Staphylococcus aureus31 (33.3)2 (66.7)66.7 33.3
Serratia marcescens21 (50)1 (50) 50 50
Enterobacter cloacae11 (100)0 (0) 100
Enterococcus raffinosus11 (100)0 (0) 100
Klebsiella ozaenae11 (100)0 (0) 100
Morganella morganii11 (100)0 (0) 100
Proteus hauseri11 (100)0(0) 100
Streptococcus gallolyticus10 (0)1(100)100
Total328214
(65.6)		114 (34.4)21.94.90.90.90.30.62.5 0.3 45.115.43.42.21.5
ESBLEscherichia coli10645 (42.5)61 (57.5)8.636.2 11.96.72.923.81 13.34.8
Klebsiella pneumoniae135 (38.5)8 (61.5)15.438.57.7 7.7 23.1 7.7
Enterobacter cloacae42 (50)2 (50) 50 2525
Citrobacter freundii32 (66.7)1 (33.3) 33.333.3 33.3
Serratia marcescens10 (0)1 (100) 100
Citrobacter amalonaticus10 (0)1 (100)100
Enterobacter gergoviae10 (0)1 (100) 100
Klebsiella aerogenes10 (0)1 (100) 100
Morganella morganii11 (100)0 (0) 100
Total13155 (43.1)76 (56.9)9.136.40.8 0.81.56.1322.70.8 11.46.80.8
Note: † IV—intravenous. * Amoxicillin/clavulanate; ** trimethoprim/sulfamethoxazole; *** piperacillin/tazobactam.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Qusad, M.; Elhalabi, I.; Ali, S.; Siddiq, K.; Loay, L.; Aloteiby, A.; Al Ansari, G.; Moustafa, B.; Olukade, T.; Al Amri, M.; et al. Urinary Tract Infections among Febrile Infants in Qatar: Extended-Spectrum-Beta-Lactamase (ESBL)-Producing Versus Non-ESBL Organisms. Antibiotics 2024, 13, 547. https://doi.org/10.3390/antibiotics13060547

AMA Style

Qusad M, Elhalabi I, Ali S, Siddiq K, Loay L, Aloteiby A, Al Ansari G, Moustafa B, Olukade T, Al Amri M, et al. Urinary Tract Infections among Febrile Infants in Qatar: Extended-Spectrum-Beta-Lactamase (ESBL)-Producing Versus Non-ESBL Organisms. Antibiotics. 2024; 13(6):547. https://doi.org/10.3390/antibiotics13060547

Chicago/Turabian Style

Qusad, Mohammad, Ihsan Elhalabi, Samer Ali, Khaled Siddiq, Lujain Loay, Abdallah Aloteiby, Ghada Al Ansari, Bassem Moustafa, Tawa Olukade, Mohammed Al Amri, and et al. 2024. "Urinary Tract Infections among Febrile Infants in Qatar: Extended-Spectrum-Beta-Lactamase (ESBL)-Producing Versus Non-ESBL Organisms" Antibiotics 13, no. 6: 547. https://doi.org/10.3390/antibiotics13060547

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop